Biomarkers of liver fibrosis and cirrhosis in chronic hepatitis C. Clinical and pathophysiological aspects

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review is devoted to the relevance of studying serological biological markers in chronic hepatitis C. Currently, it is important to develop markers for the early diagnosis of liver fibrosis and cirrhosis. The article demonstrates the possibilities of using osteopontin and hepatocyte growth factor as biomarkers of liver fibrosis and cirrhosis. Studies indicating the possibility of using these substances as targets for antifibrotic therapy are presented.

Full Text

Restricted Access

About the authors

Nikita A. Tereshkin

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Author for correspondence.
Email: nteryoshkin@gmail.com
ORCID iD: 0009-0002-3541-4150

PhD student

Russian Federation, Moscow

Vera V. Makashova

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: veramakashova@yandex.ru
ORCID iD: 0000-0002-0982-3527

Professor, MD, Leading Researcher, Clinical Department of Infectious Pathology

Russian Federation, Moscow

Zhanna B. Ponezheva

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: doktorim@mail.ru
ORCID iD: 0000-0002-6539-4878

MD, Head, Clinical Department of Infectious Pathology

Russian Federation, Moscow

Khadizhat G. Omarova

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: omarova71@inbox.ru
ORCID iD: 0000-0002-9682-2230

Cand. Med, Sci., Head, Clinical Research Department

Russian Federation, Moscow

References

  1. Stanaway J.D., Flaxman A.D., Naghavi M., Fitzmaurice C., Vos T., Abubakar I. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016; 388(10049): 1081–8. doi: 10.1016/S0140-6736(16)30579-7
  2. ВОЗ. Глобальная стратегия сектора здравоохранения по вирусным гепатитам на 2016–2021 гг. http://apps.who.int/iris/bitstream/ 10665/246177/1/WHO-HIV-2016.06-eng.pdf / [World Health Organization. Global health sector strategy on viral hepatitis 2016–2021]. (In Russ.). http://apps.who.int/iris/bitstream/10665/246177/1/ WHO-HIV-2016.06-eng.pdf
  3. Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol. Hepatol. 2022; 7(5): 396–415. doi: 10.1016/S2468-1253(21)00472-6
  4. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2022 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2023. 368 с. / [On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2022: State report]. Moscow, 2023. 368 p. (In Russ.).
  5. Abu-Dayyeh I., Chemaitelly H., Ghunaim M., Hasan T., Abdelnour A., Abu-Raddad L.J. Patterns and trends of hepatitis C virus infection in Jordan: an observational study. Front. Public Health 2023; 11: 1280427. doi: 10.3389/fpubh.2023.1280427
  6. Макашова В.В., Омарова Х.Г., Понежева Ж.Б., Ивашкова Т.А., Горелов А.В. Хронический гепатит С и его исходы: цирроз печени, гепатоцеллюлярная карцинома. Эпидемиол. инфекц. болезни. Актуал. вопр. 2023; 13(1): 99–104. doi: 10.18565/epidem.2023. 13.1.99-104 / Makashova V.V., Omarova Kh.G., Ponezheva Zh.B., Ivashkova T.A., Gorelov A.V. [Chronic hepatitis C and its outcomes: liver cirrhosis, hepatocellular carcinoma]. Epidemiоlоgy and infectious diseases. Сurrent items 2023. 13(1): 99–104. (In Russ.). doi: 10.18565/epidem.2023.13.1.99-104
  7. Kang J.G., Jang M.K., Kim J.H., Jung J.H., Park J.W., Kim S.E. et al. The diagnostic significance of hepatitis C virus antibody levels for chronic hepatitis C virus infection. Korean J. Intern. Med. 2023; 38(3): 362–71. doi: 10.3904/kjim.2022.350
  8. ВОЗ. Глобальный доклад о ходе борьбы с ВИЧ, вирусными гепатитами и инфекциями, передаваемыми половым путем, 2021 год. https://www.who.int/publications/i/item/9789240027077 / [World Health Organization. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021]. (In Russ.). https://www.who.int/ publications/i/ item/9789240027077
  9. Маев И.В., Кузнецова Е.И., Андреев Д.Н., Дичева Д.Т. Диагностическая точность предиктивных индексов оценки фиброза печени у пациентов с хроническим гепатитом С. Терапевтический архив 2020; 92(2): 24–8. doi: 10.26442/00403660.2020.02.000261 / Maev I.V., Kuznetsova E.I., Andreev D.N., Dicheva D.T. Diagnostic accuracy of predictive indexes of liver fibrosis in patients with chronic hepatitis C. Therapeutic Archive 2020; 92(2): 24–8. (In Russ.). doi: 10.26442/00403660.2020.02.000261
  10. Midia M., Odedra D., Shuster A., Midia R., Muir J. Predictors of bleeding complications following percutaneous image-guided liver biopsy: a scoping review. Diagn. Interv. Radiol. 2019; 25(1): 71–80. doi: 10.5152/dir.2018.17525
  11. Colling R., Verrill C., Fryer E., Wang L.M., Fleming K. Discrepancy rates in liver biopsy reporting. J. Clin. Pathol. 2014; 67(9): 825–7. doi: 10.1136/jclinpath-2014-202261
  12. Parikh N.D., Mehta M., Tapper E.B. FIB-4 and APRI for cirrhosis detection in a privately insured national cohort. JHEP Rep. 2023; 6(1): 100925. doi: 10.1016/j.jhepr.2023.100925
  13. Lai J.C., Liang L.Y., Wong G.L. Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases? Gastroenterol. Rep. (Oxf.). 2024; 12: goae024. doi: 10.1093/gastro/goae024
  14. Laursen T.L., Sandahl T.D., Kazankov K., George J., Grønbæk H. Liver-related effects of chronic hepatitis C antiviral treatment. World J Gastroenterol. 2020; 26(22): 2931–47. doi: 10.3748/wjg.v26.i22.2931
  15. Tang Z., Xia Z., Wang X., Liu Y. The critical role of osteopontin (OPN) in fibrotic diseases. Cytokine Growth Factor Rev. 2023; 74: 86–99. doi: 10.1016/j.cytogfr.2023.08.007
  16. Bruha R., Vitek L., Smid V. Osteopontin – A potential biomarker of advanced liver disease. Ann Hepatol. 2020; 19(4): 344–352. doi: 10.1016/j.aohep.2020.01.001
  17. Briones-Orta M.A. Avendaño-Vázquez S.E., Aparicio-Bautista D.I., Coombes J.D., Weber G.F., Syn W.K. Osteopontin splice variants and polymorphisms in cancer progression and prognosis. Biochim. Biophys. Acta Rev. Cancer 2017; 1868(1): 93–108A. doi: 10.1016/j.bbcan.2017.02.005
  18. Lamort A.S., Giopanou I., Psallidas I., Stathopoulos G.T. Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight. Cells 2019; 8(8): 815. doi: 10.3390/cells8080815
  19. Lok Z.S.Y., Lyle A.N. Osteopontin in Vascular Disease. Arterioscler. Thromb. Vasc. Biol. 2019; 39(4): 613–22. doi: 10.1161/ATVBAHA. 118.311577.
  20. Yan Z., Hu X., Tang B., Deng F. Role of osteopontin in cancer development and treatment. Heliyon. 2023; 9(10):e21055. doi: 10.1016/j.heliyon.2023.e21055
  21. Bandopadhyay M., Bulbule A., Butti R., Chakraborty G., Ghorpade P., Ghosh P. et al. Osteopontin as a therapeutic target for cancer. Expert Opin. Ther. Targets. 2014; 18(8): 883–95. doi: 10.1517/14728222.2014.925447
  22. Maeda N., Maenaka K. The Roles of Matricellular Proteins in Oncogenic Virus-Induced Cancers and Their Potential Utilities as Therapeutic Targets. Int. J. Mol. Sci. 2017; 18(10): 2198. doi: 10.3390/ijms18102198
  23. Desert R., Ge X., Song Z., Han H., Lantvit D., Chen W. et al. Role of Hepatocyte-Derived Osteopontin in Liver Carcinogenesis. Hepatol. Commun. 2022; 6(4): 692–709. doi: 10.1002/hep4.1845
  24. Wen Y., Jeong S., Xia Q., Kong X. Role of Osteopontin in Liver Diseases. Int. J. Biol. Sci. 2016; 12(9): 1121–8. doi: 10.7150/ijbs.16445
  25. Huang W., Zhu G., Huang M., Lou G., Liu Y., Wang S. Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects. Clin. Chim. Acta. 2010; 411(9–10): 675–8. doi: 10.1016/j.cca.2010.01.029
  26. Urtasun R., Lopategi A., George J., Leung T.M., Lu Y., Wang X. et al. Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology 2012; 55(2): 594–608. doi: 10.1002/hep.24701
  27. Xiao X., Gang Y., Gu Y., Zhao L., Chu J., Zhou J. et al. Osteopontin contributes to TGF-β1 mediated hepatic stellate cell activation. Dig. Dis. Sci. 2012; 57(11): 2883–91. doi: 10.1007/s10620-012-2248-7
  28. Matsue Y., Tsutsumi M., Hayashi N., Saito T., Tsuchishima M., Toshikuni N. et al. Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection. PLoS One 2015; 10(3): e0118744. doi: 10.1371/journal.pone.0118744
  29. Fouad S.A., Mohamed N.A., Fawzy M.W., Moustafa D.A. Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma. Hepat. Mon. 2015; 15(9) :e30753. doi: 10.5812/hepatmon.30753
  30. Arriazu E., Ge X., Leung T.M., Magdaleno F., Lopategi A., Lu Y. et al. Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury. Gut. 2017 66(6) :1123–37. doi: 10.1136/gutjnl-2015-310752
  31. Sobhy A., Fakhry M. M., A Azeem H.., Ashmawy A.M., Omar Khalifa H. Significance of biglycan and osteopontin as non-invasive markers of liver fibrosis in patients with chronic hepatitis B virus and chronic hepatitis C virus. J. Investig. Med. 2019; 67(3): 681–5. doi: 10.1136/jim-2018-000840
  32. Leung T.M., Wang X., Kitamura N., Fiel M.I., Nieto N. Osteopontin delays resolution of liver fibrosis. Lab. Invest. 2013; 93(10): 1082–9. doi: 10.1038/labinvest.2013.104
  33. Tang M., Guo C., Sun M.., Zhou H, Peng X., Dai J. et al. Effective delivery of osteopontin small interference RNA using exosomes suppresses liver fibrosis via TGF-β1 signaling. Front. Pharmacol. 2022; 13: 882243. doi: 10.3389/fphar.2022.882243
  34. Lurie Y., Webb M., Cytter-Kuint R., Shteingart S., Lederkremer G.Z. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J. Gastroenterol. 2015; 21(41): 11567–83. doi: 10.3748/wjg.v21.i41.11567
  35. Li N., Dou Z., Liu J., Chai B., Li Y., An X. et al. Therapeutic Effect of HGF on NASH Mice Through HGF/c-Met and JAK2-STAT3 Signalling Pathway. Ann. Hepatol. 2018; 17(3): 501–10. doi: 10.5604/01.3001.0011.7395
  36. Gharbia S., Nazarie S.R., Dinescu S., Balta C., Herman H., Peteu V.E. et al. Adipose-Derived Stem Cells (ADSCs) Supplemented with Hepatocyte Growth Factor (HGF) Attenuate Hepatic Stellate Cell Activation and Liver Fibrosis by Inhibiting the TGF-β/Smad Signaling Pathway in Chemical-Induced Liver Fibrosis Associated with Diabetes. Cells 2022; 11(21): 3338. doi: 10.3390/cells11213338
  37. Ido A., Moriuchi A., Numata M., Murayama T., Teramukai S., Marusawa H. et al. Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety. J. Transl. Med. 2011; 9: 55. doi: 10.1186/1479-5876-9-55
  38. Márquez-Coello M., Arizcorreta A., Rodríguez-Pardo M., Illanes-Álvarez F., Márquez D., Cuesta-Sancho S. et al. Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs. Sci. Rep. 2021; 11(1): 9824. doi: 10.1038/s41598-021-89370-6
  39. Narmada B.C., Kang Y., Venkatraman .L, Peng Q., Sakban R.B. et al. Hepatic stellate cell-targeted delivery of hepatocyte growth factor transgene via bile duct infusion enhances its expression at fibrotic foci to regress dimethylnitrosamine-induced liver fibrosis. Hum. Gene Ther. 2013; 24(5): 508–19. doi: 10.1089/hum.2012.158
  40. Porowski D., Wirkowska A., Hryniewiecka E., Wyzgał J., Pacholczyk M., Pączek L. Liver Failure Impairs the Intrahepatic Elimination of Interleukin-6, Tumor Necrosis Factor-Alpha, Hepatocyte Growth Factor, and Transforming Growth Factor-Beta. Biomed. Res. Int. 2015; 2015: 934065. doi: 10.1155/2015/934065
  41. Choi J.S., Jeong I.S., Park Y.J., Kim S.W. HGF and IL-10 expressing ALB::GFP reporter cells generated from iPSCs show robust anti-fibrotic property in acute fibrotic liver model. Stem. Cell Res. Ther. 2020; 11(1): 332. doi: 10.1186/s13287-020-01745-0
  42. Rohn F., Kordes C., Buschmann T., Reichert D., Wammers M., Poschmann G. et al. Impaired integrin α5 /β1 -mediated hepatocyte growth factor release by stellate cells of the aged liver. Aging Cell. 2020; 19(4): e13131. doi: 10.1111/acel.13131
  43. Oe S., Shibata M., Miyagawa K., Honma Y., Hiura M., Abe S. et al. Hepatitis A complicated with acute renal failure and high hepatocyte growth factor: A case report. World J. Gastroenterol. 2015; 21(32): 9671–4. doi: 10.3748/wjg.v21.i32.9671

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bionika Media